Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8849271 | 0.82 | GSK3A (0.36) | GSK3AGSK3BMGLL | |
| SCHEMBL697805 | 0.82 | GSK3A (0.31) | GSK3AGSK3BMGLL | |
| SCHEMBL8849196 | 0.80 | ESR1 (0.36) | L3MBTL1KMT2A | |
| SCHEMBL10579748 | 0.79 | — | — | |
| SCHEMBL13328952 | 0.78 | GAA (0.38) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL4413437 | 0.78 | GAA (0.38) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL14372133 | 0.78 | GAA (0.42) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL2870659 | 0.78 | — | — | |
| SCHEMBL20850264 | 0.77 | ALDH1A1 (0.36) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL2688393 | 0.76 | MAPK1 (0.45) | GAAL3MBTL1ALDH1A1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024237180-A1 | (METH)ACRYLATE COMPOUND PRODUCTION METHOD | 三菱瓦斯化学株式会社 | 2024-11-21 | — | — | WO | claimed |
| US-20180074079-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2018-03-15 | — | — | US | claimed |
| US-20160305967-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND | 2016-10-20 | — | — | US | claimed |
| US-9233980-B2 | Process for preparing a compound by a novel sandmeyer-like reaction using a nitroxide radical compound as a reaction catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | claimed |
| US-20140162376-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-06-12 | — | — | US | claimed |
| EP-2702400-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | Children's Hospital & Research Center at Oakland (US) | 2014-03-05 | — | — | EP | claimed |
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | claimed |
| WO-2012149473-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2012-11-01 | — | — | WO | claimed |
| EP-1095006-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY-OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH) ACRYLATE MONOMERS | Ciba SC Holding AG (CH) | 2001-05-02 | — | — | EP | claimed |
| WO-2000003965-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY- OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH)ACRYLATE MONOMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-01-27 | — | — | WO | claimed |
| US-5928558-A | STORAGE STABILITY | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| WO-2025105331-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, LAMINATE, METHOD FOR PRODUCING CURED PRODUCT, METHOD FOR PRODUCING LAMINATE, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2024237180-A1 | (METH)ACRYLATE COMPOUND PRODUCTION METHOD | 三菱瓦斯化学株式会社 | 2024-11-21 | — | — | WO | disclosed |
| EP-3992254-B1 | COMPOSITION, FILM, AND OPTICAL SENSOR | FUJIFILM CORP (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-4310556-A1 | FILM AND PHOTOSENSOR | FUJIFILM Corporation (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-1000032-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | Ciba SC Holding AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000003965-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY- OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH)ACRYLATE MONOMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999005108-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-02-04 | — | — | WO | disclosed |
| US-4332946-A | Resolution enhancing maleimide spin label for biological EPR studies | VANDERBILT UNIVERSITY (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | TYR, NOX5, NOXO1 | GAA 2809/4885L3MBTL1 4763/4885KDM4E 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.